4/10/2025, 7:06:02 pm

Bajaj Healthcare receives CDSCO approval for suvorexant insomnia trials

Bajaj Healthcare Ltd received approval from the Central Drugs Standard Control Organisation to conduct Phase III clinical trials of Suvorexant Tablets in India for treating insomnia. The trials will assess efficacy, safety, and tolerability of Suvorexant in four tablet strengths. This is a milestone step towards obtaining marketing authorisation and commercial launch.